KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.98

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil.

Sue Ann Costa Clemens, Pedro M Folegatti, Katherine R W Emary, Lily Yin Weckx, Jeremy Ratcliff, Sagida Bibi, Ana Verena De Almeida Mendes, Eveline Pipolo Milan, Ana Pittella, Alexandre V Schwarzbold, Eduardo Sprinz, Parvinder K Aley, David Bonsall, Christophe Fraser, Michelle Fuskova, Sarah C Gilbert, Daniel Jenkin, Sarah Kelly, Simon Kerridge, Teresa Lambe, Natalie G Marchevsky, Yama F Mujadidi, Emma Plested, Maheshi N Ramasamy, Peter Simmonds, Tanya Golubchik, Merryn Voysey, Andrew J Pollard, AMPHEUS Project, Oxford COVID Vaccine Trial Team

Nat Commun 12(1) 5861

PMID34615860
PMCIDPMC8494913
DOI10.1038/s41467-021-25982-w
发表日期2021-10-07
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

Several COVID-19 vaccines have shown good efficacy in clinical trials, but there remains uncertainty about the efficacy of vaccines against different variants. Here, we investigate the efficacy of ChAdOx1 nCoV-19 (AZD1222) against symptomatic COVID-19 in a post-hoc exploratory analysis of a Phase 3 randomised trial in Brazil (trial registration ISRCTN89951424). Nose and throat swabs were tested by PCR in symptomatic participants. Sequencing and genotyping of swabs were performed to determine the lineages of SARS-CoV-2 circulating during the study. Protection against any symptomatic COVID-19 caused by the Zeta (P.2) variant was assessed in 153 cases with vaccine efficacy (VE) of 69% (95% CI 55, 78). 49 cases of B.1.1.28 occurred and VE was 73% (46, 86). The Gamma (P.1) variant arose later in the trial and fewer cases (N = 18) were available for analysis. VE was 64% (-2, 87). ChAdOx1 nCoV-19 provided 95% protection (95% CI 61%, 99%) against hospitalisation due to COVID-19. In summary, we report that ChAdOx1 nCoV-19 protects against emerging variants in Brazil despite the presence of the spike protein mutation E484K.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。